


Product Details

Product name:	Anti-TNFalpha & IL17 (Remtolumab Biosimilar)	SKU:	BIO0977SM
Target Name:	TNFalpha & IL17	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P01375 & Q16552-1	Concentration:	Lyophilized
Clone#:	Remtolumab (Bispecific)	Isotype:	DVD-Ig
Reactivity:	Human	Calculated M.W.:	198.56 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-TNFalpha & IL-17 Reference Antibody (Remtolumab) is 100.00%, determined by SEC-HPLC.

Bioactivity: ELISA



Remtolumab bound to IL-17a protein, and then rebounded to secondary antibodies (human-IgG-Fc-HRP), and read OD450. As shown in fig, Remtolumab bound to huIL-17a-His, and the EC₅₀ was 0.072 nM.


ELISA



Remtolumab bound to TNFα protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP), and read OD450. As shown in fig, Remtolumab bound to hu-TNFα-Fc, and the EC₅₀ was 0.027 nM.


Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Bioactivity: FACS



Remtolumab bound to huTNF α -CHO-K cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcy PE), and test by flow cytometry. As shown in fig, Remtolumab bound to huTNF α -CHO-K cells, and the EC₅₀ was 148.700 nM.

Function: Luciferase



Co-incubation of NHDF cells with TNF- α and IL-17A protein, then with the addition of Remtolumab and incubated for 24 hours. IL-6 was measured by ELISA. As shown in fig, Remtolumab can neutralize IL-17A-induced IL-6 factor secretion, and the IC₅₀ was 0.130 nM.